International Clinical Psychopharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Antidepressant drug use and regional prescribing patterns in Germany: results from a large population-based study
Objective To consider antidepressant prescribing on a population level with a focus on regional prescribing patterns in Germany. Basic methods Based on data from about 70 million individuals covered by all statutory health insurance funds in Germany in 2010, the prevalence of antidepressant use (overall, for drug classes and individual drugs) was calculated stratified by age and sex. Regional analyses were performed on a state and also on a district level. Main results The study population comprised 68 427 464 (female: 53.0%) persons, of which 5 052 293 (7.4%) were prescribed at least one antidepr...
Source: International Clinical Psychopharmacology - August 6, 2022 Category: Psychiatry Tags: Original Articles Source Type: research

Advances in the treatment of depression
No abstract available (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - August 6, 2022 Category: Psychiatry Tags: Editorial Source Type: research

Successful clozapine rechallenge after myopericarditis: a case report
Clozapine-induced myocarditis and pericarditis are uncommon adverse effects of clozapine treatment. However, in most cases, they lead to clozapine discontinuation. Here, we describe a case of successful clozapine rechallenge after clozapine-induced myopericarditis. The patient, a 31-year-old male with treatment-resistant schizophrenia (TRS), developed dyspnea on exertion and chest pain on day 19 after the start of clozapine titration. An electrocardiogram (ECG) showed widespread, mild, convex ST interval elevation. While troponin levels were mildly elevated, the echocardiogram was unremarkable. A myopericarditis diagnosis ...
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Case report Source Type: research

The role of personality traits in following quarantine orders during the COVID-19 pandemic
This study examined the association of personality traits and characteristics of Iranian COVID-19 outpatients with their compliance to nonmandatory quarantine orders. This cross-sectional study was conducted in 2020-2021 on 97 COVID-19 outpatients. The temperament and character inventory-revised short version (TCI-RS) and a self-report checklist assessing compliance with quarantine orders were used to collect data. SPSS was used to analyze the data and P  (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Original Articles Source Type: research

Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features
Obsessive-compulsive symptoms (OCS) are often reported in patients with bipolar disorder. The aim of this study was to investigate OCS and their related clinical features in major depressive disorder (MDD). The analysis involved 482 outpatients with MDD collected within the Combining Medications to Enhance Depression outcomes trial, who were assessed with scales for depression, suicidality, irritability, hypomanic symptomatology, and other comorbid psychiatric manifestations. OCS were reported in 27% of the sample. Patients with MDD experiencing OCS were found to differ from those not experiencing OCS by a greater severity...
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Original Articles Source Type: research

Can levetiracetam improve clinical symptoms in schizophrenic patients? A randomized placebo-controlled clinical trial
This study aimed to assess the effect of levetiracetam on the severity of schizophrenia symptoms and cognitive deficits in these patients. Materials and Methods In this randomized, controlled, three-blind randomized clinical trial approved by Mashhad University of Medical Sciences, Iran (IRCT20101130005280N31), forty chronic schizophrenic patients aged 18–60 years were randomly divided into two groups of levetiracetam and placebo. The levetiracetam group received levetiracetam for 8 weeks. The symptoms were evaluated by Positive and Negative Symptoms Scale (PANSS), Stroop test, Digit Span test and Wisconsin Test a...
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Original Articles Source Type: research

Antipsychotic prescription patterns and associated factors among the elderly with psychiatric illnesses
In this study, we found that prescribing rate of antipsychotics has increased around 5.07% through the study period (from 57.25% in 2006 to 60.15% in 2015, P  (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Original Articles Source Type: research

Short-term, but not long-term, beneficial effects of concomitant benzodiazepine use on clinical course in patients with schizophrenia
In conclusion, our study indicates that short-term benzodiazepines use is associated with a better clinical course in patients with schizophrenia. Future studies should evaluate the effects of different benzodiazepines use patterns on disease prognosis with longer-term follow-up and prospective methodology and should concomitantly examine psychopathological variables. (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Original Articles Source Type: research

Mirtazapine in schizophrenia – an undeservedly overlooked option?
Mirtazapine has often been prescribed as add-on treatment for schizophrenia in patients with suboptimal response to conventional treatments. In this review, we evaluate the existing evidence for efficacy and effectiveness of add-on mirtazapine in schizophrenia and reappraise the practical and theoretical aspects of mirtazapine-antipsychotic combinations. In randomized controlled trials (RCTs), mirtazapine demonstrated favourable effects on negative and cognitive (although plausibly not depressive) symptoms, with no risk of psychotic exacerbation. Mirtazapine also may have a desirable effect on antipsychotic-induced sexual ...
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Review article Source Type: research

Strategies for improving schizophrenia treatment
No abstract available (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - June 10, 2022 Category: Psychiatry Tags: Editorial Source Type: research

Case series on aripiprazole and dopamine supersensitivity psychosis
The objective of this article is to present four cases demonstrating rapid and dramatic onset of DSP during switching to aripiprazole. In each case, a patient with a Diagnostic and statistical manual of mental disorders (5th ed.) diagnosis of schizophrenia experienced severe worsening of psychosis within 4–5 days of abrupt switching to aripiprazole from a full D2 antagonist. To our knowledge, this is the first case series characterizing the previously well-documented worsening of psychosis during switching to aripiprazole specifically as aripiprazole-induced DSP. We discuss clinical relevance, prevention and future dir...
Source: International Clinical Psychopharmacology - April 13, 2022 Category: Psychiatry Tags: Case report Source Type: research

Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial
This study confirmed the previous findings that indicate the efficacy of oxcarbazepine as same as sodium valproate. Moreover, its adverse effects resemble sodium valproate in the treatment of acutely manic patients. (Source: International Clinical Psychopharmacology)
Source: International Clinical Psychopharmacology - April 13, 2022 Category: Psychiatry Tags: Original articles Source Type: research

Increased risk of death compared to other antipsychotics in elderly clozapine users in Poland
Clozapine can cause severe adverse effects. Few epidemiologic studies have considered the effect of clozapine use in elderly patients. The aim of this study was to assess mortality in elderly patients treated with clozapine in comparison to patients treated with first- or second-generation antipsychotics. We conducted a retrospective cohort study involving 26 639 patients who were 65 years of age or older and were receiving antipsychotic medication between 2008 and 2012. Cox proportional-hazards models were used to compare the risk of death between different groups of antipsychotics after controlling for age, sex, conc...
Source: International Clinical Psychopharmacology - April 13, 2022 Category: Psychiatry Tags: Original articles Source Type: research

Social withdrawal and neurocognitive correlates in schizophrenia
Poor neurocognitive performance has been associated with poor functional outcome in schizophrenia (SCZ) in past studies. Nonetheless, the likely association between neurocognition and social withdrawal has never been investigated. The aim of our study was to investigate in a large and heterogeneous sample of SCZ patient cross-sectional associations between neurocognitive domains and social withdrawal. The sample included 761 SCZ patients who completed the baseline visit in the CATIE study. Neurocognition was assessed by a comprehensive battery of tests resulting in five domain scores and a composite score. Social withdrawa...
Source: International Clinical Psychopharmacology - April 13, 2022 Category: Psychiatry Tags: Original articles Source Type: research

Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial
This study aimed to investigate the efficacy and safety of antitumor necrosis factor-alpha (TNF-α) therapy using adalimumab in patients with chronic schizophrenia. This is a randomized, double-blind, placebo-controlled clinical trial carried out at Roozbeh Hospital (Tehran, Iran) from June 2020 to October 2021. The patients were randomly divided into two parallel adalimumab + risperidone and placebo + risperidone groups. Participants in the intervention group received adalimumab subcutaneous injection (40 mg) by pen-injector at weeks 0 and 4. Using the Positive and Negative Symptoms Scale (PANSS), patients’ positive and...
Source: International Clinical Psychopharmacology - April 13, 2022 Category: Psychiatry Tags: Original articles Source Type: research